NCT04867707CompletedPhase 2
Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 25 Apr 2025
Brief summary (registry, in English)
The objective is to determine if neuraminidase inhibition with zanamivir is efficacious as a therapeutic strategy to restore endothelial function in T2D patients.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- First submitted
- 27 Apr 2021
- Start date
- 14 Jul 2021
- Primary completion date
- 18 Oct 2024
- Lead sponsor
- University of Missouri-Columbia
- Diseases
- Type 2 diabetes
- NCT number
- NCT04867707
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 14
- From 14 Jul 2021 to the primary completion date, 18 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Immunosuppressant therapy
- Hormone replacement therapy
- Intranasal live attenuated influenza vaccine (LAIV) given within 2 weeks before zanamivir administration or a planned dose within 48 hours after zanamivir administration. Product insert states to avoid zanamivir administration with intranasal live attenuated influenza vaccine (LAIV).
Other illness
- Cardiovascular disease including myocardial infraction, heart failure, coronary artery disease, stroke
- History of chronic renal or hepatic disease
- Active cancer
- Autoimmune diseases
- History of asthma or chronic obstructive pulmonary disease.
- History of allergic reaction to lactose or milk proteins
Other
- Excessive alcohol consumption (\>14 drinks/week for men, \>7 drinks/week for women)
- Current tobacco use
- Pregnancy (Premenopausal women will be required to complete a urine pregnancy test before participation)
Who the study is looking for
- Men and women with a BMI of 25-39 kg/m2
- Ages 45-64 years at randomization.
- Diagnosis of T2D classified based on physician diagnosis.
- No vulnerable populations (e.g., prisoners, pregnant, children) will be enrolled.
Age in the registry: 45 years to 64 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Missouri, School of Medicine Clinical Research Center Coordinator of this site? Confirm its status | Columbia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.